

25.02.2019

08:45 - 09:30 Opening and welcome + Honorary award Keynote lecture **Amphithéâtre Bordeaux**

Moderation: J. Tabernero¹, A.A. Adjei², ¹Medical Oncology, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES, ²Oncology, Mayo Clinic, Rochester, US

08:45 - 08:45 **Session DOI**

08:45 - 08:50 **Welcome address - ESMO**

J. Tabernero, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES

08:50 - 08:55 **Welcome address - TAT 2019 Scientific Committee**

A.A. Adjei, Mayo Clinic, Rochester, US

08:55 - 09:00 **Presentation of the TAT 2019 Honorary Award**

A.A. Adjei, Mayo Clinic, Rochester, US

09:00 - 09:30 **Development of Cyclin-Dependent Kinase Inhibitors: A Brief History and Future Directions**

G. Shapiro, Dana Farber Cancer Institute, Boston, US

09:35 - 11:00	Liquid biopsies as biomarkers for early drug development	Amphithéâtre Bordeaux
	Moderation: L. Ellis ¹ , C. Massard ² , ¹ Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, US, ² Ditep, Gustave Roussy - Cancer Campus, Villejuif, FR	
09:35 - 09:35	Session DOI	
09:35 - 09:45	Introduction	
	<u>C. Massard</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
09:45 - 10:00	Technical insights on liquid biopsies: Available techniques, sensitivity, GMP	
	<u>P. Laurent-Puig</u> , Paris Descartes University, Paris, FR	
10:00 - 10:15	Driving the pharmacological audit trail through liquid biopsies	
	<u>J. De Bono</u> , The Institute of Cancer Research (ICR), London, GB	
10:15 - 10:30	Single circulating tumour cell genomics as a biomarker for early drug development	
	<u>N. Stoecklein</u> , Heinrich-Heine-University Düsseldorf, Düsseldorf, DE	
10:30 - 10:45	Tumour mutational burden during treatment: Implications for immuno-oncology	
	<u>N. Rizvi</u> , Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US	
10:45 - 11:00	Q&A and conclusion	
	<u>L. Ellis</u> , The University of Texas MD Anderson Cancer Center, Houston, US	

11:30 - 13:00	Emerging therapeutic strategies	Amphithéâtre Bordeaux
	Moderation: R. Plummer ¹ , T. Yap ² , D.S. Tan ³ , ¹ The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle upon Tyne, GB, ² Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, US, ³ Medical Oncology, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG	
11:30 - 11:30	Session DOI	
11:30 - 11:35	Introduction	
	<u>R. Plummer</u> , Northern Institute for Cancer Research University of Newcastle, Newcastle upon Tyne, GB	
11:35 - 11:50	DNA polymerase Theta (POLθ) as an anticancer target	
	<u>G. Higgins</u> , University of Oxford, Oxford, GB	
11:50 - 12:05	Targeting the WNT pathway for cancer therapy	
	<u>D.S. Tan</u> , NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG	
12:05 - 12:20	HIF-2a	
	<u>E. Jonasch</u> , The University of Texas MD Anderson Cancer Center, Houston, US	
12:20 - 12:35	Cancer evolution as a therapeutic target	
	<u>A. Bardelli</u> , University Of Torino - Candiolo Cancer Institute - FPO - IRCCS, Candiolo, IT	
12:35 - 12:50	Clinical development of oxidative phosphorylation (OXPHOS) inhibitors	
	<u>T. Yap</u> , The University of Texas MD Anderson Cancer Center, Houston, US	
12:50 - 12:55	Q&A	

13:00 - 14:00	Meet the Professor - TRK fusion cancer: A tumour-agnostic treatment target	Room 342
	Moderation: U. Lassen ¹ , C. Marchiò ² , ¹ Dept. Of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, ² Department Of Medical Sciences, Università degli Studi di Torino, Torino, IT	
13:00 - 13:00	Session DOI	
13:00 - 13:20	TRK fusion cancer: epidemiology, treatment and clinical cases <u>U. Lassen</u> , Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK	
13:20 - 13:40	NTRK gene fusions: mechanisms and testing <u>C. Marchiò</u> , Università degli Studi di Torino, Torino, IT	
13:15 - 14:00	Workshop: How to peer review a manuscript	Room 341
	Moderation: L. Ellis ¹ , A.A. Adjei ² , ¹ Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, US, ² Oncology, Mayo Clinic, Rochester, US	
13:15 - 13:15	Session DOI	
13:15 - 13:20	Introduction <u>L. Ellis</u> , The University of Texas MD Anderson Cancer Center, Houston, US	
13:20 - 13:30	What YOU should include in your manuscripts <u>L. Ellis</u> , The University of Texas MD Anderson Cancer Center, Houston, US	
13:30 - 13:50	What editors (and authors) look for in good peer review <u>A.A. Adjei</u> , Mayo Clinic, Rochester, US	
13:50 - 14:00	Conclusion and take-away message <u>L. Ellis</u> , The University of Texas MD Anderson Cancer Center, Houston, US	

- 14:05 - 15:20 Proffered Paper session : Immunotherapy** **Amphithéâtre Bordeaux**
Moderation: J. De Bono¹, C. Massard², ¹The Institute of Cancer Research (ICR), London, GB, ²Ditep, Gustave Roussy - Cancer Campus, Villejuif, FR
- 14:05 - 14:05 **Session DOI**
- 14:05 - 14:20 **30 - Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials**
A. Varga¹, A. Bernard-Tessier¹, E. Auclin², L. Mezquita Pérez¹, C. Baldini¹, D. Planchard³, A. Marabelle⁴, A. Hollebecque¹, B. Besse⁴, C. Massard⁴, ¹Gustave Roussy, Villejuif, FR, ²Hopital European George Pompidou, Paris, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR
- 14:20 - 14:30 **Q&A**
J. De Bono¹, C. Massard², ¹The Institute of Cancer Research and Royal Marsden, London, GB, ²Gustave Roussy - Cancer Campus, Villejuif, FR
- 14:30 - 14:45 **20 - A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors**
A. Tolcher¹, D. Fang², Y. Li³, Y. Tang⁴, J. Ji², H. Wang², R. Karim¹, C. Rosas¹, Y. Huang², Y. Zhai², ¹NEXT OncologyTM, San Antonio, US, ²Ascentage Pharma, Inc, Suzhou, CN, ³Ascentage Pharma Group, Inc, Rockville, US, ⁴Affiliates of Ascentage Pharma Group Corp Limited, Hong Kong, CN
- 14:45 - 14:55 **Q&A**
J. De Bono¹, C. Massard², ¹The Institute of Cancer Research (ICR), London, GB, ²Gustave Roussy - Cancer Campus, Villejuif, FR
- 14:55 - 15:10 **290 - The 18-year-old clinical trial inclusion limit is a major barrier in the access to immunotherapies and targeted therapies for adolescents and young adults (AYAs) with cancer**
T. De Rojas¹, A. Neven¹, M. Garcia-Abos², L. Moreno³, N. Gaspar⁴, J. Peron¹, ¹EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, ²Hospital Donostia, San Sebastian, ES, ³Hospital Niño Jesús, Madrid, ES, ⁴Gustave Roussy Cancer Campus, Villejuif, FR
- 15:10 - 15:20 **Q&A**
J. De Bono¹, C. Massard², ¹The Institute of Cancer Research and Royal Marsden, London, GB, ²Gustave Roussy - Cancer Campus, Villejuif, FR

- 15:45 - 17:15 Learning from haemato-oncology trials** **Amphithéâtre Bordeaux**
Moderation: O. Bernard¹, V. Ribrag², ¹Gustave Roussy - Cancer Campus, Villejuif, FR,
²Ditep, Institut Gustave Roussy, Villejuif, FR
- 15:45 - 15:45 **Session DOI**
- 15:45 - 15:50 **Introduction**
V. Ribrag, Institut Gustave Roussy, Villejuif, FR
- 15:50 - 16:10 **Epigenetic dysregulation in hematological malignancies**
O. Bernard, Gustave Roussy - Cancer Campus, Villejuif, FR
- 16:10 - 16:30 **PRMT5 in hematological malignancies**
A. Dhar, GlaxoSmithKline USA, Collegeville, US
- 16:30 - 16:50 **BiTEs for cancer therapy**
R.C. Bargou, University of Würzburg, Würzburg, DE
- 16:50 - 17:10 **Application of CRISPR screen to guide therapy for lymphoma**
H.G. Wendel, Memorial Sloan Kettering Cancer Center, New York, US
- 17:10 - 17:15 **Q&A**

26.02.2019

08:00 - 08:45 Workshop: How to write a grant **Room 341**
Moderation: J. De Bono¹, J. Mateo², ¹The Institute of Cancer Research (ICR), London, GB,
²Vall d'Hebron University Hospital, Barcelona, ES

08:00 - 08:00 **Session DOI**

08:00 - 08:05 **Introduction**

J. De Bono, The Institute of Cancer Research (ICR), London, GB

08:05 - 08:30 **What you must know about writing a research grant proposal**

J. De Bono, The Institute of Cancer Research (ICR), London, GB

08:30 - 08:45 **Writing your first Young Investigator grant**

J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

09:00 - 10:30	Immune checkpoint combinations: How to marry rationally Moderation: G. Giaccone ¹ , M. Gutierrez ² , ¹ Oncology, Lombardi Cancer Center Georgetown University, Washington DC, US, ² Medical Oncology, The John Theurer Cancer Center, Hackensack, US	Amphithéâtre Bordeaux
09:00 - 09:00	Session DOI	
09:00 - 09:05	Maximizing the potential of IO combinations: Successes and failures <u>G. Giaccone</u> , Lombardi Cancer Center Georgetown University, Washington DC, US	
09:05 - 09:25	The rationale behind immunotherapy combinations <u>G. Freeman</u> , Dana Farber Cancer Institute, Boston, US	
09:25 - 09:45	Leveraging single-cell technologies for discovery of novel IO drug combinations <u>B. Izar</u> , Dana-Farber Cancer Institute, Boston, US	
09:45 - 10:05	Preclinical models to assess timing of combination regimens <u>S. Khleif</u> , Georgetown University, Washington, US	
10:05 - 10:25	Immuno-oncology combination in patients with pre-existing molecular alteration (EGFR ALK BRAF and other) <u>M. Gutierrez</u> , Hackensack Meridian Health, Hackensack, US	
10:25 - 10:30	Q&A	

- 11:00 - 12:15 Proffered Paper session: New and early developments with new concepts** **Amphithéâtre Bordeaux**
Moderation: G. Giaccone¹, A.A. Adjei², ¹Oncology, Lombardi Cancer Center Georgetown University, Washington DC, US, ²Oncology, Mayo Clinic, Rochester, US
- 11:00 - 11:00 **Session DOI**
- 11:00 - 11:15 **80 - ⁸⁹Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors**
D. Giesen¹, L. Broer¹, M. Lub-De Hooge¹, I. Popova², B. Howng², O. Vasiljeva², E.G.E. De Vries¹, M. Pool³, ¹University Medical Center Groningen, Groningen, NL, ²CytomX Therapeutics Inc., South San Francisco, US, ³Leiden University Medical Center, Leiden, NL
- 11:15 - 11:25 **Q&A**
G. Giaccone¹, A.A. Adjei², ¹Lombardi Cancer Center Georgetown University, Washington DC, US, ²Mayo Clinic, Rochester, US
- 11:25 - 11:40 **70 - Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)**
A. Hollebecque¹, J. De Bono², R. Plummer³, N. Isambert⁴, P. Martin-Romano⁵, E. Baudin⁶, S. Mora⁷, E. Filvaroff⁸, M. Lamba⁹, Z. Nikolova¹⁰, ¹Gustave Roussy, Villejuif, FR, ²The Institute of Cancer Research (ICR), London, GB, ³Northern Institute for Cancer Research University of Newcastle, Newcastle upon Tyne, GB, ⁴Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶Gustave Roussy Institut de Cancérologie, Villejuif, FR, ⁷Celgene Institute Translational Research Europe-CITRE, Sevilla, ES, ⁸Celgene Corporation, San Francisco, UM, ⁹Celgene Corporation, Summit, UM, ¹⁰Celgene International Switzerland, Boudry, CH
- 11:40 - 11:50 **Q&A**
G. Giaccone¹, A.A. Adjei², ¹Lombardi Cancer Center Georgetown University, Washington DC, US, ²Mayo Clinic, Rochester, US
- 11:50 - 12:05 **250 - Use of CTTA to predict treatment response in patients with EGFR T790M+ NSCLC treated with osimertinib**
W.L. Tan¹, T.A. Tran Nguyen², T.S. Koh², T. Priyanthi Henedige², C. Yip², S.H. Tan², D. Tan¹, C.H. Thng², D. Lim¹, Q.S. Ng¹, ¹National Cancer Center Singapore, Singapore, SG, ²National Cancer Centre, SINGAPORE, SG
- 12:05 - 12:15 **Q&A**
G. Giaccone¹, A.A. Adjei², ¹Lombardi Cancer Center Georgetown University, Washington DC, US, ²Mayo Clinic, Rochester, US

- 12:45 - 13:30 Workshop: How to choose a drug to study, biomarkers, etc. Room 341**
Moderation: G. Schwartz¹, S. Bates², ¹Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ²Medicine Hematology/medical Oncology, Columbia University, New York, US
- 12:45 - 12:45 **Session DOI**
- 12:45 - 12:55 **Drug development: Lessons from failure**
S. Bates, Columbia University, New York, US
- 12:55 - 13:05 **Drug development: Lessons from success**
G. Schwartz, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US
- 13:05 - 13:25 **Round table discussion**
S. Bates¹, G. Schwartz², ¹Columbia University, New York, US, ²Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US
- 13:25 - 13:30 **Conclusion and take-away message**
S. Bates¹, G. Schwartz², ¹Columbia University, New York, US, ²Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

13:35 - 15:05	Immune checkpoint inhibitors with targeted agents: Challenging marriages	Amphithéâtre Bordeaux
	Moderation: I. Melero ¹ , G. Curigliano ² , ¹ Laboratory Of Immunology, Clinica Universitaria de Navarra, Pamplona, ES, ² Early Drug Development for Innovative Therapies Division, University Of Milano, Istituto Europeo di Oncologia, Milan, IT	
13:35 - 13:35	Session DOI	
13:35 - 13:40	Introduction: Making challenging marriages work <u>T. Yap</u> , MD Anderson Cancer Center, Houston, US	
13:40 - 14:00	PARP and PD-1/PDL1 inhibition <u>G. Curigliano</u> , Istituto Europeo di Oncologia, Milan, IT	
14:00 - 14:20	PI3K/AKT + PD-1/PD-L1 inhibition <u>S. Ansell</u> , Mayo Clinic, Rochester, US	
14:20 - 14:40	MEK + PD-1/PD-L1 inhibition <u>C. Massard</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
14:40 - 15:00	Epigenetics and Immunotherapy <u>I. Melero</u> , Clinica Universitaria de Navarra, Pamplona, ES	
15:00 - 15:05	Q&A	

15:30 - 17:30 Methodological issues in IO **Amphithéâtre Bordeaux**

Moderation: J. Tabernero¹, A.A. Adjei², ¹Medical Oncology, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES, ²Oncology, Mayo Clinic, Rochester, US

15:30 - 15:30 **Session DOI**

15:30 - 15:35 **Introduction**

15:35 - 15:55 **Biomarkers & endpoints**

A. Marabelle, Gustave Roussy, Villejuif, FR

15:55 - 16:15 **Imaging biomarkers**

E.G.E. De Vries, University Medical Center Groningen, Groningen, NL

16:15 - 16:35 **Scheduling, dose optimisation**

E. Calvo, Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES

16:35 - 16:55 **Complex innovative designs**

Y. Shyr, Vanderbilt University School of Medicine, Nashville, US

16:55 - 17:15 **Report from MDICT**

L. Seymour, Canadian Cancer Trials Group, Kingston, CA

17:15 - 17:30 **Discussion**

17:30 - 18:00	Selected Poster Presentation	Amphithéâtre Bordeaux
	Moderation: J. De Bono ¹ , E. Calvo ² , ¹ The Institute of Cancer Research (ICR), London, GB, ² Dept. Early Clinical Drug Development, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES	
17:30 - 17:30	Session DOI	
17:30 - 17:35	4P - Novel applications of MVA to improve outcomes in immunooncology	
	C. Heery ¹ , C. Pico-Navarro ² , T. Adams ³ , L. Bauman ⁴ , J. Medina ³ , M. Hinterberger ⁵ , A. Heiseke ³ , H. Lauterbach ³ , H. Hochrein ³ , ¹ Bavarian Nordic, Morrisville, US, ² Bavarian Nordic, Cancer Immunotherapy Division, Madrid, ES, ³ Bavarian Nordic GmbH, Martinsried (Planegg), DE, ⁴ Bavarian Nordic, Inc., Roswell, US, ⁵ Bavarian Nordic, Planegg, DE	
17:35 - 17:40	Q&A	
	J. De Bono ¹ , E. Calvo ² , ¹ The Institute of Cancer Research (ICR), London, GB, ² Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES	
17:40 - 17:45	9P - Safety profile and therapeutic efficacy of one cycle of [¹⁷⁷Lu]prostate-specific membrane antigen (PSMA) in end stage metastatic castration-resistant prostate cancer patients with low performance status	
	M. Gupta ¹ , P. Choudhury ² , S. Rawal ¹ , H. Goel ³ , V. Talwar ¹ , K. Dutta ¹ , A. Singh ¹ , ¹ Rajiv Gandhi Cancer Institute & Research Centre, Delhi, IN, ² Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN, ³ Amity University, Uttar Pradesh, IN	
17:45 - 17:50	Q&A	
	J. De Bono ¹ , E. Calvo ² , ¹ The Institute of Cancer Research (ICR), London, GB, ² Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES	
17:50 - 17:55	30P - Dynamic change in the distribution of cancer types in oncology phase I trials	
	J. Sato, K. Itahashi, T. Shimizu, T. Koyama, S. Kondo, Y. Fujiwara, N. Yamamoto, National Cancer Center Hospital, Tokyo, JP	
17:55 - 18:00	Q&A	
	J. De Bono ¹ , E. Calvo ² , ¹ The Institute of Cancer Research (ICR), London, GB, ² Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES	
18:00 - 18:45	Cocktail and Poster viewing	Hall Bordeaux
	Moderation: J. De Bono ¹ , E. Calvo ² , ¹ The Institute of Cancer Research (ICR), London, GB, ² Dept. Early Clinical Drug Development, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES	
18:00 - 18:05	1P - PIWI proteins play oncogenic functions in pancreatic cancer	

W. Li¹, J. Martinez Useros², M. Fernández-Aceñero³, N. García Carbonero², J. García-Foncillas⁴, ¹University Hospital Fundacion Jimenez Diaz, Madrid, ES, ²University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ³Clinico San Carlos University Hospital, Madrid, ES, ⁴University Hospital "Fundacion Jimenez Diaz", MADRID, ES

- 18:05 - 18:10 **4P - Novel applications of MVA to improve outcomes in immunooncology**
C. Heery¹, C. Pico-Navarro², T. Adams³, L. Bauman⁴, J. Medina³, M. Hinterberger⁵, A. Heiseke³, H. Lauterbach³, H. Hochrein³, ¹Bavarian Nordic, Morrisville, US, ²Bavarian Nordic, Cancer Immunotherapy Division, Madrid, ES, ³Bavarian Nordic GmbH, Martinsried (Planegg), DE, ⁴Bavarian Nordic, Inc., Roswell, US, ⁵Bavarian Nordic, Planegg, DE
- 18:10 - 18:15 **5P - Establishment and application of a panel of PBMC-humanized mouse tumor models in cancer immunotherapy**
L. Bourre¹, L. Zhang¹, S. Qi¹, H. Wu¹, L. Zhao¹, X. An¹, W. Tan², X. Fu², M. Qiao¹, Q. Shi¹, W. Yang¹, ¹Crown Bioscience Inc., San Diego, US, ²Taicang Blood Center, Taicang, Suzhou, CN
- 18:15 - 18:20 **9P - Safety profile and therapeutic efficacy of one cycle of [¹⁷⁷Lu]prostate-specific membrane antigen (PSMA) in end stage metastatic castration-resistant prostate cancer patients with low performance status**
M. Gupta¹, P. Choudhury², S. Rawal¹, H. Goel³, V. Talwar¹, K. Dutta¹, A. Singh¹, ¹Rajiv Gandhi Cancer Institute & Research Centre, Delhi, IN, ²Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN, ³Amity University, Uttar Pradesh, IN
- 18:20 - 18:25 **6P - Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors**
S. Amaral¹, M. Casal Moura², J. Carvalho¹, A. Chaves¹, E. Jesus¹, G. Sousa¹, ¹Portuguese Institute of Oncology, Coimbra, PT, ²University of Porto, Porto, PT
- 18:25 - 18:25 **10P - Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?**
L. Leroy¹, T. Satar¹, C. Baldini², P. Martin-Romano¹, A. Hollebecque², J.-M. Michot¹, V. Ribrag¹, C. Massard³, X. Paoletti¹, S. Postel Vinay¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy, Villejuif, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR
- 18:25 - 18:25 **11P - Photosensitizer-based multimodal nanocomposites as a theranostic agent for near infrared (NIR)-guided cancer-targeting synergistic chemo-phototherapy**
T. Ponraj¹, R. Vivek², M. Paulpandi¹, K. Vimala³, A. Vasanthakumar¹, S. Kannan⁴, ¹Bharathiar University, Coimbatore, IN, ²Rajiv Gandhi Centre for Biotechnology,, Thiruvananthapuram, IN, ³Periyar University, salem, IN, ⁴Periyar University, Salem, IN
- 18:25 - 18:25 **12P - Targeting HIF1/EPAS1 in hypoxia by novel 7-amino-6-halogeno-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides**
A. Scherbakov¹, G. Buravchenko², L. Dezhenkova², A. Shchekotikhin², ¹N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ²Gause Institute of New Antibiotics,

Moscow, RU

- 18:25 - 18:25 **13P - Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways**
G. Umapathy¹, J. Van Den Eynden², D. Cervantes-Madrid³, J. Szydzik³, J. Guan³, R. Palmer³, B. Hallberg³, ¹University of Gothenburg - The Sahlgrenska Academy, Goteborg, SE, ²Gothenburg University, Gothenburg, SE, ³The Sahlgrenska Academy at Gothenburg University, Gothenburg, SE
- 18:25 - 18:25 **14P - Butein inhibits solid tumors cell viability, colony, and tumor growth via STAT3 signaling pathway and enhance the anti-cancer effects of Frondoside-A and camptothecin**
S. Attoub¹, S. Sulaiman², K. Arafat², ¹College of Medicine and Health Sciences / United Arab Emirates University, Al Ain, AE, ²College of Medicine & Health Sciences / United Arab Emirates University, Al Ain, AE
- 18:25 - 18:25 **15P - ATM loss in NSCLC increases sensitivity to cisplatin and PARP inhibition**
D.G. Bebb¹, L. Petersen², J. Moore², A. Elegbede², S. Lees-Miller², ¹Tom Baker Cancer Centre, Calgary, CA, ²University of Calgary, Calgary, CA
- 18:25 - 18:25 **16P - Inhibition of PDE4 sensitizes drug resistant NSCLC to TKI therapy**
S. Mukherjee, D. Suresh, A. Upendran, R. Kannan, University of Missouri, Columbia, US
- 18:25 - 18:25 **17P - microRNA-16-5p enhances radiosensitivity through modulating cyclin D1/E1&&**
L. Gan, F. Wang, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, CN
- 18:25 - 18:25 **18P - Choline transporter-like protein 1 (CTL1/SLC44A1) is a therapeutic target molecule for prostate cancer therapy**
M. Inazu, I. Saiki, H. Uchino, T. Yamanaka, Tokyo Medical University, Tokyo, JP
- 18:25 - 18:25 **19P - Preclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC)**
C.L. Lee¹, S. Toomey², A. Farrelly³, B. Hennessy³, ¹St Vincents University Hospital, Dublin, IE, ²Royal College of Surgeons in Ireland, Dublin, IE, ³Royal College of Surgeons in Ireland, Beaumont Hospital, DUBLIN, IE
- 18:25 - 18:25 **20P - Nischarin expression in colon cancer**
M. Cavic, M. Vidosavljevic, S. Radulovic, J. Grahovac, Institute for Oncology and Radiology of Serbia, Belgrade, RS
- 18:25 - 18:25 **21P - Evaluation of magnetic nanoparticle of irinotecan for personalized treatment of colorectal cancer**
A. Singh, Indian Institute of Science, Bangalore, IN

18:25 - 18:25

22P - Therapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer

H. Kim, S. Son, Hanyang University, Seoul, KR

18:25 - 18:25 **23P - Matricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer**

S. Son, H. Kim, I. Shin, Hanyang University, Seoul, KR

18:25 - 18:25 **24P - Reactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients**

O. Trifanescu¹, F. Topliceanu², B.-A. Gusoiu¹, L. Gales¹, R. Anghel³, ¹National Institute of Oncology A.Treistioreanu, Bucharest, RO, ²Central University Emergency Military Hospital, Bucharest, RO, ³UNIVERSITY OF MEDICINE AND PHARMACY "CAROL DAVILA", Bucharest, RO

18:25 - 18:25 **26P - Texture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy**

M. Wang, X. Ma, West China Hospital, Sichuan University, chengdu, CN

18:25 - 18:25 **27P - Detection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens**

Y.S. Yap¹, D. Ho², R.C.-H. Ng¹, C.H.-T. Chan¹, A.S.-G. Lee¹, I.B.-H. Tan¹, S.B.H. Ng², ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Genome Institute of Singapore, Singapore, SG

18:25 - 18:25 **28P - Simultaneous unbiased and absolute quantification of a 500 protein panel in pancreatic cancer plasma using HRM mass spectrometry**

H. Yu, J. Vowinckel, C. Escher, D. Heinzmann, N. Dupuis, Biognosys AG, Schlieren, CH

18:25 - 18:30 **30P - Dynamic change in the distribution of cancer types in oncology phase I trials**

J. Sato, K. Itahashi, T. Shimizu, T. Koyama, S. Kondo, Y. Fujiwara, N. Yamamoto, National Cancer Center Hospital, Tokyo, JP

18:30 - 18:30 **31P - Comprehensive genomic profiling of Chinese esophageal squamous cell carcinoma patients**

Y. Ji¹, Y. Wu², W. Fu³, L. Liu⁴, Z. Tian⁵, S. Wen⁵, K. Zhang⁶, M. Yao⁷, A. Liu⁷, Y. Zhou⁷, ¹Zhejiang Cancer Hospital, Hangzhou, CN, ²Dongguan people's hospital, Dongguan, CN, ³Affiliated cancer hospital and institute of Guangzhou Medical University, Guangzhou, CN, ⁴Jiangsu province hospital, Nanjing, CN, ⁵Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ⁶People's Hospital of Wuzhou, Wuzhou, CN, ⁷OrigiMed, Shanghai, CN

18:30 - 18:30 **32P - Clinical correlation between different CKIT exon mutations and clinical outcome imatinib mesylate treatment in gastrointestinal stromal tumor (GIST) patients**

G. Zakaria¹, N. Allahloubi², A. Bahnasy³, O. Khorshid³, ¹Cairo Oncology Center Cairo University-CairoCure, Cairo, EG, ²NCi, Cairo, EG, ³NCI, Cairo, EG

- 18:30 - 18:30 **33P - Proteomic analysis of UKF-NB-4 cells reveals a stimulatory activity of MT-3 on cellular senescence and apoptosis**
M.A. Merlos Rodrigo¹, H. Buchtelova², V. Strmiska², A. Jimenez Jimenez², I. Casal³, V. Adam², Z. Heger², ¹Medical Faculty, University of Brno, Prague, CZ, ²Mendel University of Brno, Brno, CZ, ³CIB-CSIC, Madrid, ES
- 18:30 - 18:30 **34P - Impact of treatment with bilastine for PD-1/PD-L1 inhibitors induced rash**
T. Hirata, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, JP
- 18:30 - 18:30 **35P - Enhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7**
Y. Xie, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, CN
- 18:30 - 18:30 **36P - Structural diversity of the cardenolide calotropin renders it as a targeted therapy for harnessing TNBC progression through tuning nitric oxide (NO) levels**
R.A. Ellayeh¹, R. Youness¹, H. Askary², A. Abdelmotaal³, R. Assal¹, ¹German University in Cairo, Cairo, EG, ²Cairo University, Cairo, EG, ³King Khalid University, Abha, SA
- 18:30 - 18:30 **37P - Genomics and pharmacogenomics analyses of cancer cell lines using the CellMinerCDB and CellMiner web-applications**
W. Reinhold¹, Y. Pommier², ¹NCI /NIH, Bethesda, US, ²National Cancer Institute, Bethesda, US

27.02.2019

09:00 - 10:30 Monotherapy vulnerability- Cell cycle checkpoint and DNA damage/repair inhibitors **Amphithéâtre Bordeaux**

Moderation: G. Schwartz¹, G. Shapiro², ¹Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ²Medical Oncology, Dana Farber Cancer Institute, Boston, US

09:00 - 09:00 **Session DOI**

09:00 - 09:05 **Introduction**

G. Shapiro, Dana-Farber Cancer Institute, Boston, US

09:05 - 09:25 **DNA repair deficiency in ovarian cancer: Use of short-term patient-derived organoids to predict DNA repair inhibitor response**

A. D'Andrea, Dana-Farber Cancer Institute, Boston, US

09:25 - 09:45 **Monotherapy vulnerability to ATR inhibition: Tumors harboring ALT, ATM deficiency and other alterations**

R. Plummer, Northern Institute for Cancer Research University of Newcastle, Newcastle upon Tyne, GB

09:45 - 10:05 **Replication stress and DNA repair inhibitors**

G. Shapiro, Dana Farber Cancer Institute, Boston, US

10:05 - 10:25 **Trial designs and targeting DNA repair**

J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

10:25 - 10:30 **Q&A**

11:00 - 12:30	KRAS	Amphithéâtre Bordeaux
	Moderation: U. Banerji ¹ , S. Bates ² , ¹ Drug Development Unit , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ² Medicine Hematology/medical Oncology, Columbia University, New York, US	
11:00 - 11:00	Session DOI	
11:00 - 11:05	Introduction	
	<u>S. Bates</u> , Columbia University, New York, US	
11:05 - 11:25	Allele specific KRAS G12C inhibitors: from mechanism to modulation of antitumor effect	
	<u>P. Lito</u> , Memorial Sloan-Kettering Cancer Center, New York, US	
11:25 - 11:45	Update on the KRAS program at NCI	
	<u>D. Nissley</u> , Frederick National Laboratory/Leidos, Frederick, US	
11:45 - 12:05	Phase I trial of RO5126766 a MEK-RAF inhibitor in solid tumours and myeloma driven by RAS driven cancers	
	<u>U. Banerji</u> , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB	
12:05 - 12:25	Inhibiting K-ras in the clinic: The saga continues	
	<u>A.A. Adjei</u> , Mayo Clinic, Rochester, US	
12:25 - 12:30	Q&A	

13:30 - 15:00 Targeting oncogenes generated by gene fusions Amphithéâtre Bordeaux
Moderation: U. Banerji, Drug Development Unit , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

13:30 - 13:30 **Session DOI**

13:30 - 13:35 **Introduction**

U. Banerji, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

13:35 - 13:55 **NTRK**

R. Doebele, University of Colorado, Aurora, US

13:55 - 14:15 **Targeting RET**

V. Subbiah, The University of Texas MD Anderson Cancer Center, Houston, US

14:15 - 14:35 **TPRSSZ / FGFR**

J. Bellmunt, PSMAR-IMIM Research Institute, Barcelona, ES

14:35 - 14:55 **ROS1 and ALK**

R. Doebele, University of Colorado Cancer Center, Aurora, US

14:55 - 15:00 **Q&A**

15:00 - 15:15 Take home messages and close Amphithéâtre Bordeaux
Moderation: C. Massard, Ditep, Gustave Roussy - Cancer Campus, Villejuif, FR

15:00 - 15:00 **Session DOI**

15:00 - 15:15 **Take home messages and close**

C. Massard, Gustave Roussy - Cancer Campus, Villejuif, FR